Xvivo Perfusion AB Asset Resilience Ratio
Xvivo Perfusion AB asset resilience ratio. Xvivo Perfusion AB (XVIVO) has an Asset Resilience Ratio of 12.30% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read XVIVO current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Xvivo Perfusion AB (2016–2025)
Asset resilience ratio of Xvivo Perfusion AB from 2016 to 2025. This chart shows how Xvivo Perfusion AB's Asset Resilience Ratio has changed over time. See Xvivo Perfusion AB (XVIVO) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Xvivo Perfusion AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Xvivo Perfusion AB's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr292.09 Million | 12.3% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr292.09 Million | 12.30% |
Asset Resilience Insights
- Moderate Liquidity: Xvivo Perfusion AB has 12.30% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Xvivo Perfusion AB Industry Peers by Asset Resilience Ratio
Compare Xvivo Perfusion AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
GN Store Nord
CO:GN |
Medical Devices | -4.56% |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212 |
Medical Devices | 6.09% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
VIROMED MEDICAL NA O.N.
XETRA:VME |
Medical Devices | 0.03% |
|
Affluent Medical SAS
PA:AFME |
Medical Devices | 0.03% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
Xvivo Perfusion AB Asset Resilience Ratio by Year (2016–2025)
Xvivo Perfusion AB asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Xvivo Perfusion AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.30% | Skr292.09 Million ≈ $31.43 Million |
Skr2.37 Billion ≈ $255.49 Million |
-4.98pp |
| 2024-12-31 | 17.28% | Skr415.22 Million ≈ $44.68 Million |
Skr2.40 Billion ≈ $258.57 Million |
-21.25pp |
| 2023-12-31 | 38.54% | Skr846.09 Million ≈ $91.05 Million |
Skr2.20 Billion ≈ $236.28 Million |
+20.19pp |
| 2022-12-31 | 18.34% | Skr317.86 Million ≈ $34.21 Million |
Skr1.73 Billion ≈ $186.51 Million |
-7.51pp |
| 2021-12-31 | 25.85% | Skr398.70 Million ≈ $42.91 Million |
Skr1.54 Billion ≈ $166.01 Million |
-4.95pp |
| 2020-12-31 | 30.79% | Skr354.24 Million ≈ $38.12 Million |
Skr1.15 Billion ≈ $123.79 Million |
+5.59pp |
| 2019-12-31 | 25.21% | Skr159.95 Million ≈ $17.21 Million |
Skr634.49 Million ≈ $68.28 Million |
-6.68pp |
| 2018-12-31 | 31.89% | Skr187.06 Million ≈ $20.13 Million |
Skr586.61 Million ≈ $63.13 Million |
-4.38pp |
| 2017-12-31 | 36.27% | Skr195.32 Million ≈ $21.02 Million |
Skr538.54 Million ≈ $57.96 Million |
+29.15pp |
| 2016-12-31 | 7.12% | Skr24.87 Million ≈ $2.68 Million |
Skr349.30 Million ≈ $37.59 Million |
-- |
About Xvivo Perfusion AB
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidn… Read more